These materials are not for human consumption, veterinary use, diagnostic procedures, cosmetic use, therapeutic applications, or medical treatment
Mol Cell Endocrinol 418:4254 Lorenz M, Evers A, Wagner M (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity
Randomized controlled trials before the issue of CVOTs by the FDA in 2008 mainly focused on the efficacy of the blood glucose-lowering effects and a broad spectrum of adverse effects, with limited numbers of cardiovascular adverse events and relatively short follow-up duration
Make sure you get enough calcium, D3, B12, and protein
Whether GLP-1 medications have direct or indirect effects on the menstrual cycle independent of weight loss is a question researchers are now better positioned to study, in part because of work like this